A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions

Tomo Ando, Hisato Takagi, Alexandros Briasoulis, Tesfaye Telila, David P. Slovut, Luis Afonso, Cindy L. Grines, Theodore Schreiber

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: To summarize the published data of combined transcatheter aortic and mitral valve intervention (CTAMVI). Background: CTAMVI, a combination of either transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve (TAViV) and transcatheter mitral valve replacement (TMVR), transcatheter mitral valve-in-valve/valve-in-ring (TMViV/ViR), or percutaneous mitral valve repair (PMVR) is an attractive alternative in high-surgical risk patients with combined aortic and mitral valve disease. However, its procedural details and clinical outcomes have not been well described. Methods: We performed a systematic review of all the published articles from PUBMED and EMBASE. Results: A total of 37 studies with 60 patients were included. The indication for CTAMVI was high or inoperable surgical risk and symptomatic severe aortic stenosis (92%) or severe aortic regurgitation (8%) combined with moderate to severe/severe mitral stenosis (30%) or moderate/severe mitral regurgitation (65%) or both (5%). In majority of the cases, aortic valve intervention was performed prior to the mitral valve. Mortality rate were 25% for TAVR+TMVR (range 42 days to 10 months), 17% for TAVR+TMViV/ViR (range 13 days to 6 months), 0% for TAViV+TMViV/ViR (range 6-365 days), and 15% for TAVR/ViV+PMVR (range 17 days to 419 days). Significant (more than moderate) paravalvular regurgitation post-procedure was rare. Conclusions: CTAMVI appears to confer reasonable clinical outcome. Further large study is warranted to clarify the optimal strategy, procedural details and clinical outcomes in the future.

Original languageEnglish (US)
JournalCatheterization and Cardiovascular Interventions
DOIs
StateAccepted/In press - 2017

Fingerprint

Aortic Valve
Mitral Valve
Aortic Valve Insufficiency
Mitral Valve Stenosis
Aortic Valve Stenosis
Mitral Valve Insufficiency

Keywords

  • Mitraclip
  • Transcatheter aortic valve replacement
  • Transcatheter mitral valve repair
  • Valve-in-valve

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions. / Ando, Tomo; Takagi, Hisato; Briasoulis, Alexandros; Telila, Tesfaye; Slovut, David P.; Afonso, Luis; Grines, Cindy L.; Schreiber, Theodore.

In: Catheterization and Cardiovascular Interventions, 2017.

Research output: Contribution to journalArticle

Ando, Tomo ; Takagi, Hisato ; Briasoulis, Alexandros ; Telila, Tesfaye ; Slovut, David P. ; Afonso, Luis ; Grines, Cindy L. ; Schreiber, Theodore. / A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions. In: Catheterization and Cardiovascular Interventions. 2017.
@article{871badd020164e46ad5f74f462752081,
title = "A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions",
abstract = "Objectives: To summarize the published data of combined transcatheter aortic and mitral valve intervention (CTAMVI). Background: CTAMVI, a combination of either transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve (TAViV) and transcatheter mitral valve replacement (TMVR), transcatheter mitral valve-in-valve/valve-in-ring (TMViV/ViR), or percutaneous mitral valve repair (PMVR) is an attractive alternative in high-surgical risk patients with combined aortic and mitral valve disease. However, its procedural details and clinical outcomes have not been well described. Methods: We performed a systematic review of all the published articles from PUBMED and EMBASE. Results: A total of 37 studies with 60 patients were included. The indication for CTAMVI was high or inoperable surgical risk and symptomatic severe aortic stenosis (92{\%}) or severe aortic regurgitation (8{\%}) combined with moderate to severe/severe mitral stenosis (30{\%}) or moderate/severe mitral regurgitation (65{\%}) or both (5{\%}). In majority of the cases, aortic valve intervention was performed prior to the mitral valve. Mortality rate were 25{\%} for TAVR+TMVR (range 42 days to 10 months), 17{\%} for TAVR+TMViV/ViR (range 13 days to 6 months), 0{\%} for TAViV+TMViV/ViR (range 6-365 days), and 15{\%} for TAVR/ViV+PMVR (range 17 days to 419 days). Significant (more than moderate) paravalvular regurgitation post-procedure was rare. Conclusions: CTAMVI appears to confer reasonable clinical outcome. Further large study is warranted to clarify the optimal strategy, procedural details and clinical outcomes in the future.",
keywords = "Mitraclip, Transcatheter aortic valve replacement, Transcatheter mitral valve repair, Valve-in-valve",
author = "Tomo Ando and Hisato Takagi and Alexandros Briasoulis and Tesfaye Telila and Slovut, {David P.} and Luis Afonso and Grines, {Cindy L.} and Theodore Schreiber",
year = "2017",
doi = "10.1002/ccd.27256",
language = "English (US)",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A systematic review of reported cases of combined transcatheter aortic and mitral valve interventions

AU - Ando, Tomo

AU - Takagi, Hisato

AU - Briasoulis, Alexandros

AU - Telila, Tesfaye

AU - Slovut, David P.

AU - Afonso, Luis

AU - Grines, Cindy L.

AU - Schreiber, Theodore

PY - 2017

Y1 - 2017

N2 - Objectives: To summarize the published data of combined transcatheter aortic and mitral valve intervention (CTAMVI). Background: CTAMVI, a combination of either transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve (TAViV) and transcatheter mitral valve replacement (TMVR), transcatheter mitral valve-in-valve/valve-in-ring (TMViV/ViR), or percutaneous mitral valve repair (PMVR) is an attractive alternative in high-surgical risk patients with combined aortic and mitral valve disease. However, its procedural details and clinical outcomes have not been well described. Methods: We performed a systematic review of all the published articles from PUBMED and EMBASE. Results: A total of 37 studies with 60 patients were included. The indication for CTAMVI was high or inoperable surgical risk and symptomatic severe aortic stenosis (92%) or severe aortic regurgitation (8%) combined with moderate to severe/severe mitral stenosis (30%) or moderate/severe mitral regurgitation (65%) or both (5%). In majority of the cases, aortic valve intervention was performed prior to the mitral valve. Mortality rate were 25% for TAVR+TMVR (range 42 days to 10 months), 17% for TAVR+TMViV/ViR (range 13 days to 6 months), 0% for TAViV+TMViV/ViR (range 6-365 days), and 15% for TAVR/ViV+PMVR (range 17 days to 419 days). Significant (more than moderate) paravalvular regurgitation post-procedure was rare. Conclusions: CTAMVI appears to confer reasonable clinical outcome. Further large study is warranted to clarify the optimal strategy, procedural details and clinical outcomes in the future.

AB - Objectives: To summarize the published data of combined transcatheter aortic and mitral valve intervention (CTAMVI). Background: CTAMVI, a combination of either transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve-in-valve (TAViV) and transcatheter mitral valve replacement (TMVR), transcatheter mitral valve-in-valve/valve-in-ring (TMViV/ViR), or percutaneous mitral valve repair (PMVR) is an attractive alternative in high-surgical risk patients with combined aortic and mitral valve disease. However, its procedural details and clinical outcomes have not been well described. Methods: We performed a systematic review of all the published articles from PUBMED and EMBASE. Results: A total of 37 studies with 60 patients were included. The indication for CTAMVI was high or inoperable surgical risk and symptomatic severe aortic stenosis (92%) or severe aortic regurgitation (8%) combined with moderate to severe/severe mitral stenosis (30%) or moderate/severe mitral regurgitation (65%) or both (5%). In majority of the cases, aortic valve intervention was performed prior to the mitral valve. Mortality rate were 25% for TAVR+TMVR (range 42 days to 10 months), 17% for TAVR+TMViV/ViR (range 13 days to 6 months), 0% for TAViV+TMViV/ViR (range 6-365 days), and 15% for TAVR/ViV+PMVR (range 17 days to 419 days). Significant (more than moderate) paravalvular regurgitation post-procedure was rare. Conclusions: CTAMVI appears to confer reasonable clinical outcome. Further large study is warranted to clarify the optimal strategy, procedural details and clinical outcomes in the future.

KW - Mitraclip

KW - Transcatheter aortic valve replacement

KW - Transcatheter mitral valve repair

KW - Valve-in-valve

UR - http://www.scopus.com/inward/record.url?scp=85028609894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028609894&partnerID=8YFLogxK

U2 - 10.1002/ccd.27256

DO - 10.1002/ccd.27256

M3 - Article

C2 - 28862381

AN - SCOPUS:85028609894

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

ER -